Epigenomics AG (FRA:ECX)

Epigenomics AG Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	0.34	0.9	6.2	0.84
Revenue Growth (YoY)	-	-62.29%	-85.51%	636.70%	-25.16%
Cost of Revenue	-	0.06	0.47	0.14	0.15
Gross Profit	-	0.28	0.43	6.07	0.7
Selling, General & Admin	0.28	4.21	3	7.51	7.3
Research & Development	-	-	-	3.11	3.66
Other Operating Expenses	0.84	-0.32	8.8	-0.39	-0.15
Operating Expenses	1.13	4.46	12.15	10.23	10.81
Operating Income	-1.13	-4.18	-11.73	-4.16	-10.11
Interest Expense	-	-	-0.08	-0.05	-0.06
Interest & Investment Income	0.04	0.04	0.09	0.01	0.02
Currency Exchange Gain (Loss)	0.02	-0.09	0.72	1.82	-1.51
Other Non Operating Income (Expenses)	-	-	-0	-0.02	-0
EBT Excluding Unusual Items	-1.07	-4.23	-11	-2.4	-11.66
Gain (Loss) on Sale of Investments	-2.28	-0.23	-6.31	-	-
Gain (Loss) on Sale of Assets	-	-	-	-0.01	-
Pretax Income	-3.35	-4.46	-17.3	-2.41	-11.66
Income Tax Expense	-	-	-	0.02	0.02
Net Income	-3.35	-4.46	-17.3	-2.43	-11.69
Net Income to Common	-3.35	-4.46	-17.3	-2.43	-11.69
Shares Outstanding (Basic)	1	1	1	1	0
Shares Outstanding (Diluted)	1	1	1	1	0
Shares Change (YoY)	2.76%	4.93%	45.14%	93.95%	24.03%
EPS (Basic)	-3.82	-5.23	-21.28	-4.33	-40.45
EPS (Diluted)	-3.82	-5.23	-21.28	-4.33	-40.45
Free Cash Flow	-1.2	-5.71	-10.71	-4.19	-9.58
Free Cash Flow Per Share	-1.37	-6.69	-13.17	-7.47	-33.16
Gross Margin	-	83.19%	47.27%	97.81%	82.78%
Operating Margin	-	-1232.15%	-1304.56%	-67.10%	-1201.19%
Profit Margin	-	-1316.81%	-1924.80%	-39.14%	-1387.89%
Free Cash Flow Margin	-	-1684.66%	-1191.77%	-67.50%	-1137.89%
EBITDA	-1.12	-2.83	-4.71	-4.06	-10.01
EBITDA Margin	-	-	-	-65.40%	-
D&A For EBITDA	0.01	1.35	7.02	0.11	0.11
EBIT	-1.13	-4.18	-11.73	-4.16	-10.11
EBIT Margin	-	-	-	-67.10%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.